Core--Formulations

核心--配方

基本信息

批准号：
7682140
负责人：
Joe A. McDonough
金额：
$ 10.7万
依托单位：
RHODE ISLAND HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/7682140
关键词：
Adhesives Animal Model Aspartate Biological Assay CCR5 gene Calcium Cells Chemicals Compatible Complex Conceptrol Condition Cytoplasm Data Defensins Drug Formulations Encapsulated Endocytosis Evaluation Exclusion Future Gel Gene Silencing Glycol Glycols Goals Grant HIV HIV-1 Hela Cells High Pressure Liquid Chromatography Human Papillomavirus In Vitro Inflammatory Response Lipids Macaca Marketing Mediator of activation protein Methodology Methods Microcapsules drug delivery system Microscopic Mucous Membrane Natural Immunity Nucleic Acids Particle Size Peptides Pharmaceutical Preparations Placebos Polyethyleneimine Purpose RNA RNA Interference Rate Research Institute Sexually Transmitted Diseases Simplexvirus Testing Time Toxic effect Transfection U-Series Cooperative Agreements Vagina Vaginal Gel Virus Diseases Viscosity base capsule desire enhanced green fluorescent protein fluorophore in vivo light scattering microbicide nano nonaarginine novel particle prevent rectal research study residence size transmission process uptake

项目摘要

The formulations core will be led by Southwest Research Institute, a commercial entity with expertise in formulating drug for mucosal delivery. The singular purpose of this Core will be to develop a nanocapsular formulation of short interfering RNA (siRNA) that will be appropriate for mucosal delivery. To accomplish this goal, various nanocapsular formulations will be synthesized and tested for their ability to incorporate and deliver siRNA to the cellular cytoplasm; Initial experiments will use a siRNA molecule conjugated to a fluorophore, this allowing rapid microscopic evaluation of the efficiency of cellular entry. Once an optimum formulation is identified, this Core will produce formulations of siRNA targeting macaque CCR5 and enhanced green fluorescent protein in year 1. These products will be supplied to Projects by Ramratnam and Lambert for in vitro and in vivo evaluations of gene silencing potency and toxicity. These evaluations will allow us to decide upon an optimum formulation conditions that will be used to formulate siRNAs identified by Projects by Herold and Lambert in future years of the grant.

配方核心将由商业实体西南研究所领导具有为粘膜递送的药物配制的专业知识。这个核心的单一目的将是开发短干扰RNA（siRNA）的纳米胶囊配方，这将适合粘膜输送。为了实现这一目标，将合成各种纳米胶囊配方并测试了它们将siRNA掺入细胞细胞质的能力；最初的实验将使用连接到荧光团的siRNA分子，这允许快速微观评估细胞进入效率。一旦确定了最佳公式，该核心将产生靶向猕猴CCR5和增强的绿色荧光蛋白的siRNA制剂 1年级。这些产品将由Ramratnam和Lambert提供给项目，以进行体外和体内评估基因沉默的效力和毒性。这些评估将使我们能够决定最佳将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，赫罗德（Herold）和兰伯特（Lambert）确定了sirnas 赠款年。